enGene interim CMO William Grossman acquires common shares worth $10,050.94

PUBT · 1d ago
enGene interim CMO William Grossman acquires common shares worth $10,050.94
  • William Grossman, interim chief medical officer, bought 5,102 enGene Therapeutics common shares at USD 1.97 each.
  • Post-transaction stake rose to 5,102 common shares, held directly.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001552781-26-000501), on September 24, 2026, and is solely responsible for the information contained therein.